Enzon, Inc.

Bristol-myers Squibb Compnay

Roche Innovation Center Copenhagen A/s

Viiv Healthcare UK (no.5) Limited

Enzon Pharmaceuticals, Inc.

Viiv Healthcare UK Limited

Belrose Pharma, Inc.

Annapurna Pendri

Richard B Greenwald

Samuel Gerritz

Guo Li

Chongqing Sun

Anthony J Martinez

Yun Hwang Choe

Hong Zhao

Bruce A Ellsworth

William R Ewing

Natesan Murugesan

Weixu Zhai

Nicholas A Meanwell

Richard Eric Olson

Yanting Huang

Peter Hagedorn

Marianne Lerbech Jensen

Angela Marie Cacace

Jere E Meredith, Jr

Nino Devidze

James K Loy

Carl J Baldick

Paul Michael Scola

Tao Wang

Zhongxing Zhang

B Narasimhulu Naidu

Makonen Belema

John A Bender

Li-Qiang Sun

Robert G Gentles

Eric Mull

Zhong Yang

Brett R Beno

Doree F Sitkoff

Zhengxiang Gu

David R Langley

Richard B Sulsky

Philip Michael Sher

Qian Zhao

Jacques Banville

Michael A Walker

Ivar M McDonald

Guixue Yu

Alan Xiangdong Wang

Roger Remillard

Shirong Zhu

Amarendra B Mikkilineni

Robert A Fridell

Ying Wang

Dharmpal S Dodd

Zhiwei Yin

Shoshana L Posy

Yasutsugu Ueda

Gan Wang

Manoj Patel

Van N Nguyen

Katharine A Grant-Young

Stanley V D'Andrea

Kevin M Peese

John D Matiskella

Gang Wu

Margaret E Sorenson

Bradley C Pearce

George L Trainor

Manoranjan Panda

Francis Beaulieu

Zhongyu Wang

Srinivasan Thangathirupathy

Carl Ouellet

Serge Plamondon

Chong-qing Sun

Ximao Wu

Ivar M Mcdonald

Rajesh Onkardas Bora

Haibo Liu

Shuhao Shi

Selvakumar Kumaravel

Chen Li

Swanee E Jacutin-Porte

Christopher W Cianci

Laura Akullian D'Agostino

Mallikarjuna Rao Mettu

Ting T Yin

Shilpa Maheshwarappa Holehatti

Zhuping Ma

Stephen R Johnson

Yun H Choc

Sean Kim

The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.

Inhibitors of protein tyrosine phosphatase, compositions, and methods of use

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

A compound of Formula I is set forth, including pharmaceutically acceptable salts thereof: wherein Het is a 5 or 6-membered heterocycle with &#x2014;N, &#x2014;O, or &#x2014;S adjacent to the &#x2014;Ar substituent or adjacent to the point of attachment for the &#x2014;Ar substituent;Ar is aryl or heteroaryl;R is &#x2014;CH, &#x2014;CHF, or &#x2014;CH&#x2550;CH;W is &#x2014;NO, &#x2014;Cl, &#x2014;Br, &#x2014;CHO, &#x2014;CH&#x2550;CH, or &#x2014;CN;X is &#x2014;Cl, &#x2014;CH, or &#x2014;CN;Y is &#x2014;CH or &#x2014;N; andZ is C-Calkyl, C-Ccycloalkyl, substituted aryl, substituted heteroaryl, OR, or NHR, wherein Ris selected from the group of H, aryl, heteroaryl, C-Calkyl and C-Ccycloalkyl. This compound is useful in compositions for the prevention and treatment of influenza virus.

Piperazine analogs as broad-spectrum influenza antivirals

The invention provides for compounds of formula I  Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Growing community of inventors

South Glastonbury, CT, United States of America

Annapurna Pendri